FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal 
Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
HASBROUCK HEIGHTS, N.J., May 08, 2017 -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Following Nymox's announcement of the Company's filing for marketing approval of Fexapotide Triflutate for enlarged prostate (BPH) in Europe, Nymox is pleased to announce a teleconference with shareholders at 4:30 p.m. EDT on Wednesday May 10, 2017. The call-in number will be reported prior to the teleconference call.
Shareholder questions in advance are welcomed and can be sent by email to: [email protected]
Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of fexapotide. Nymox undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2016, and its Quarterly Reports.
Contact: Paul Averback Nymox Pharmaceutical Corporation 800-93NYMOX www.nymox.com
